Clinical Trial Update: Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma [Phase 1]

View source ↗

Summary

A phase 1 trial investigating Nilotinib in combination with either Dabrafenib/Trametinib or Encorafenib/Binimetinib in metastatic melanoma with BRAF mutation; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• Dabrafenib (Dabrafenib)
• Encorafenib (encorafenib)
• Nilotinib (nilotinib)
• Trametinib (trametinib)

Snippet

Sponsor: Rina Plattner | Conditions: Metastatic Melanoma, BRAF Gene Mutation | Phase 1 | Status: RECRUITING